en · de · es · fr · pt
nad-notes.peptides6908.com › Topic › Background And Pharmacological Mechanism — 2026 Update

Background And Pharmacological Mechanism — 2026 Update

By Editorial Desk · published 2026-05-11 · last reviewed 2026-06-30 · Topic

reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-06-30. Anything still debated is marked as such rather than presented as settled.

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SReported for the free base
Molecular weight437.9 g/molCalculated from the formula
Primary targetREV-ERBα and REV-ERBβNuclear receptors involved in circadian regulation
SolubilitySoluble in DMSO and ethanolPoorly soluble in water
Typical storage-20 °C, desiccatedProtect from light and moisture

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Related pages on this site

Handling Storage and Quality Control

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Analytical Detection and Laboratory Handling

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Reference notes

c7orf26 interacts uniquely with 11 different proteins, according to the Mentha interactome browser. In particular, c7orf26 interacts with the entire family of 'INTS' (Integrator Complex Subunit 1–7). The Integrator Complex associates with the C-terminal domain of RNA polymerase II large subunit. It is involved in the transcription and processing of their transcripts. INTS mediates recruitment of cytoplasmic dynein to the nuclear envelope. Outside of the INTS gene family, c7orf26 interacts with AK5, HDGF, and ASUN. According to Guirato et al. (2018), there may be some evidence that regions on chromosome 7 may be directly linked to a nuclear estrogen receptor (ESR2) that modulates cancer cell proliferation and tumor growth. In another journal article by Fu et al. (2014), there is further indication that regions along chromosome 7, located between open reading frames 20-30, directly correlate to cellular functions of a hepatoma-derived growth factor (HDGF), another way of expressing normal function in tumorigenesis.

Ralser's two research groups use LC–MS to analyze the proteomes and metabolomes of microorganisms. The main model organism is the baking yeast (Saccharomyces cerevisiae), but other species, such as pathogenic fungus Candida albicans and the fission yeast Schizosaccharomyces pombe, are used too. His lab not only uses LC–MS, but also develops novel LC–MS methods and protocols that improve detection accuracy, speed, and throughput. Specializing in data-independent acquisition, the group has developed scanning SWATH MS and Zeno SWATH MS in collaboration with MS manufacturer SCIEX. Both methods greatly improve upon SWATH MS, which was developed in Switzerland in 2012. The group additionally developed an acquisition method—DIA-NN—that uses neural networks. But proteins and metabolites are not the only focus: in 2022 the lab developed a protocol for the accurate quantification of DNA methylation using LC–MS. Key research topics include:

14N + p → 11C + 4He − 2.92 MeV It can also be produced by fragmentation of 12C by shooting high-energy 12C at a target. Carbon-11 is commonly used as a radioisotope for the radioactive labeling of molecules in positron emission tomography. Among the many molecules used in this context are the radioligands [11C]DASB and [11C]Cimbi-5. Due to the short half-life, the chemical reactions used to manipulate the radioisotope as generated and incorporate it into a biomolecule must be efficient. Popular key intermediates include [11C]phosgene, for carboxylation-related reactions, though other synthons, such as [11C]carbonyl fluoride and [11C]carbon dioxide, are also being explored. For methylation, [11C]iodomethane and related synthons are used.

== History == Lente insulin arose from research into ways to alter the pharmacokinetics of bovine or porcine insulin products. Prior to the late 1940s, insulin products were derived from pork or beef sources, and then used virtually unaltered as "short-acting" insulin products. It was known by 1950 that the addition of protamine or zinc could alter the duration of action of these insulin products, and in 1952, K. Hallas-Møller at Novo Nordisk produced the first commercial insulin zinc suspension for use in humans. For decades, lente insulin was used as a basal insulin, designed to mimic the body's continual slow release of insulin throughout the day. Compared to NPH insulin, lente insulin has a similar but more protracted loss of action after a dose is administered. In the 1990s, recombinant DNA technology allowed for the mass production of the human insulin protein in yeast or bacteria. This led to formulations of recombinant lente human insulin products by the early 2000s. However, lente insulin began to fall out of favor with doctors in the mid-2000s, when insulin analogues such as glargine began to be approved. Insulin analogues made by recombinant DNA production methods have less variation in their strength and purity between doses and batches. Furthermore, while lente insulin (and NPH) have a definitive peak in effect, insulin analogs have a much less pronounced peak, making for more predictable effects and less risk of hypoglycemia.

=== Beauty supplements === Beauty supplements, particularly those aimed at improving the health of skin, hair, and nails, are commonly marketed within the wellness and supplement markets. These products typically include ingredients, such as collagen, which is reputed to improve the appearance and condition of skin, hair, and nails. Other typical ingredients include biotin, keratin, and omega-3 fatty acids, which are promoted for their alleged benefits to skin and hair health. Demand for these beauty supplements has risen markedly in the 21st century. Despite the apparent rise in demand, scientific evidence supporting the efficacy of ingredients like biotin for the purpose of hair growth remains unproven.

Sources: en.wikipedia.org

Notes from published material

Guns: 6 × .50 caliber (12.7mm) AN/M2 Browning machine guns with 1,840 total rounds (380 rounds for each on the inboard pair and 270 rounds for each of the outer two pair) Rockets: 6 or 10 × 5.0 in (127 mm) T64 HVAR rockets (P-51D-25, P-51K-10 on) Bombs: 1 × 100 lb (45 kg) or 250 lb (110 kg) bomb or 500 lb (230 kg) bomb on hardpoint under each wing

Rhodium (from Greek: ῥόδον rhodon, meaning 'rose') was discovered in 1803 by William Hyde Wollaston, soon after he discovered palladium. He used crude platinum ore presumably obtained from South America. His procedure started by dissolving the ore in aqua regia, precipitating the platinum as ammonium chloroplatinate by adding ammonium chloride (NH4Cl). Adding zinc precipitated a mixture of copper, lead, palladium, and rhodium. Dilute nitric acid dissolved the copper and lead. Dissolving the remainder in aqua regia again and adding sodium chloride, the solution was evaporated to yield rose-red Na3[RhCl6]·nH2O. After extraction with hot ethanol, additional zinc displaced the rhodium in the ionic compound, releasing the rhodium as free metal. For decades, the rare element had only minor applications; for example, by the turn of the century, rhodium-containing thermocouples were used to measure temperatures up to 1800 °C. They have exceptionally good stability in the temperature range of 1300 to 1800 °C. The first major application was electroplating for decorative uses and as corrosion-resistant coating. The introduction of the three-way catalytic converter by Volvo in 1976 increased the demand for rhodium. The previous catalytic converters used platinum or palladium, while the three-way catalytic converter used rhodium to reduce the amount of NOx in the exhaust.

==== Protection from UV radiation ==== Ultraviolet UV-A and UV-B radiation is harmful to living systems. An important tool used to deal with UV exposure is the biosynthesis of small-molecule sunscreens. MAAs have been implicated in UV radiation protection. The genetic basis for this implication comes from the observed induction of MAA synthesis when organisms are exposed to UV radiation. This has been observed in aquatic yeasts, cyanobacteria, marine dinoflagellates and some Antarctic diatoms. MAAs have also been identified in 572 species of other algae : 45 species in Chlorophyta, 41 species in Phaeophyta, 486 species in Rhodophyta which also present anti-aging, anti-inflammatory, antioxidative and wound healing properties. When MAAs absorb UV light the energy is dissipated as heat. UV-B photoreceptors have been identified in cyanobacteria as the molecules responsible for the UV light induced responses, including synthesis of MAAs. Helioguard™365 containing Porphyra-334 and shinorine derived from Porphyra umbilicalis is already a creme on the market were developed by Mibelle AG biochemistry and shows preventive effects against UVA. An MAA known as palythine, derived from seaweed, has been found to protect human skin cells from UV radiation even in low concentrations. "MAAs, in addition to their environmental benefits, appear to be multifunctional photoprotective compounds," says Dr. Karl Lawrence, lead author of a paper on the research. "They work through the direct absorption of UVR [ultraviolet radiation] photons, much like the synthetic filters.

The formation of such a heterochromatin region, though not its maintenance, is Dicer-dependent, presumably because Dicer is required to generate the initial complement of siRNAs that target subsequent transcripts. Heterochromatin maintenance has been suggested to function as a self-reinforcing feedback loop, as new siRNAs are formed from the occasional nascent transcripts by RdRP for incorporation into local RITS complexes. The relevance of observations from fission yeast mating-type regions and centromeres to mammals is not clear, as heterochromatin maintenance in mammalian cells may be independent of the components of the RNAi pathway.

Open fuel cycle: the cycle starts with the mining of uranium, goes through the fuel fabrication and ends with the direct disposal of the spent fuel. Closed fuel cycle: the spent fuel stored for a long time can be safely handled and it undergoes reprocessing in order to recover and recycle a large amount of it.

Sources: en.wikipedia.org

Further detail

He was succeeded by Kazuo Ito as president. In April 2002, Ajinomoto reorganized itself into food, amino acid, and medicine divisions, and owned subsidiaries for frozen foods, fats, and oils. In February 2003, Ajinomoto and Unilever completed a joint venture agreement in six countries and regions of Asia. Because of this, Ajinomoto launched the brand VONO to replace its use of the Knorr brand, and in the process established its own brand identity. In July 2003, Ajinomoto bought the French company Orsan from the UK-based Tate and Lyle Group, renaming Orsan to AJI-NO-MOTO Foods, Europe. In November 2005, AJI-NO-MOTO Pharmaceuticals USA, Inc. was liquidated, and its assets and functions were merged into AJI-NO-MOTO Pharmaceuticals, Europe. In January 2006, Ajinomoto bought the cooking sauce and condiments manufacturer Amoy Food from the French dairy company Groupe Danone. In 2009, the company released "Ajinomoto" to commemorate the 100th anniversary of its foundation.

The oil industry remained largely state-owned, with the wholly state-owned National Oil Corporation retaining a 70% share in Libya's oil industry, the government also imposed a 93% tax on all oil that foreign companies produced in Libya. Price controls and subsidies over oil and food remained in place, and state-provided benefits such as free education, universal healthcare, free housing, free water and free electricity remained in place. Libya also changed its stance on the WTO after the removal of technocrat Shukri Ghanem, with Gaddafi condemning the WTO as a neocolonial terrorist organisation, and urging African and Third World countries not to join it. While there was no accompanying political liberalization, with Gaddafi retaining predominant control, in March 2010, the government devolved further powers to the municipal councils. Rising numbers of reformist technocrats attained positions in the country's governance; best known was Gaddafi's son and heir apparent Saif al-Islam Gaddafi, who was openly critical of Libya's human rights record. He led a group who proposed the drafting of a new constitution, although it was never adopted. Involved in encouraging tourism, Saif founded several privately run media channels in 2008, but after criticizing the government, they were nationalized in 2009.

== Z == Shuguang Zhang (PhD 1988). American biochemist at the Massachusetts Institute of Technology, known for his discovery of self-assembling peptides. Guggenheim Fellow and Member, Austrian Academy of Sciences. Donald Zilversmit (1919–2010). Dutch-American nutritional biochemist at Cornell University, with many contributions to the understanding of the relationship between diet and cardiovascular disease. Member Natl. Acad. Sci. USA.

Studies have measured δ34S values of bone collagen, though the interpretation of these values was not reliable until quality criteria were published in 2009. Though bone collagen is abundant in skeletal remains, less than 1% of the tissue is made of sulfur, making it imperative that these studies carefully assess the meaning of bone collagen δ34S values.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

How does it work?

It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.

Is it proven to increase endurance in humans?

No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

Network